Fuller & Thaler Asset Management
CORT icon

Fuller & Thaler Asset Management’s Corcept Therapeutics CORT Stock Holding History

Fuller & Thaler Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-438,342
Closed -$6.89M – 515
2018
Q2 		$6.89M Buy
+438,342
New +$7.63M 0.07% 180
2018
Q1 		– Sell
-440,300
Closed -$7.95M – 774
2017
Q4 		$7.95M Buy
440,300
+295,200
+203% +$5.35M 0.1% 147
2017
Q3 		$2.8M Buy
145,100
+89,700
+162% +$1.34M 0.03% 215
2017
Q2 		$654K Hold
55,400
– – 0.01% 304
2017
Q1 		$607K Buy
55,400
+10,800
+24% +$94.9K 0.01% 298
2016
Q4 		$324K Buy
44,600
+36,100
+425% +$283K ﹤0.01% 326
2016
Q3 		$55K Buy
+8,500
New +$49.4K ﹤0.01% 569

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fuller & Thaler Asset Management's CORT Position: Q3 2018 in Review

Fuller & Thaler Asset Management sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 438,342 shares — an estimated $6.89M sold.

Fuller & Thaler Asset Management first reported a position in CORT in Q3 2016 and held it in 7 quarters. The position peaked at $7.95M in Q4 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

  • Fuller & Thaler Asset Management reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 438,342 Corcept Therapeutics shares in Q3 2018, an estimated $6.89M.
  • Fuller & Thaler Asset Management first reported a position in Corcept Therapeutics in Q3 2016 and held it in 7 quarters.
  • Fuller & Thaler Asset Management's Corcept Therapeutics position peaked at $7.95M in Q4 2017.
  • 207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.